MetLife Investment Advisors LLC purchased a new stake in shares of Fluidigm Co. (NASDAQ:FLDM) during the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund purchased 16,104 shares of the medical research company’s stock, valued at approximately $214,000.
Several other institutional investors also recently bought and sold shares of the company. BlackRock Inc. raised its position in Fluidigm by 9.1% in the fourth quarter. BlackRock Inc. now owns 2,139,878 shares of the medical research company’s stock worth $18,445,000 after purchasing an additional 178,429 shares in the last quarter. Vanguard Group Inc. grew its stake in Fluidigm by 9.5% during the third quarter. Vanguard Group Inc. now owns 1,410,526 shares of the medical research company’s stock worth $10,565,000 after buying an additional 121,815 shares during the last quarter. Millennium Management LLC grew its stake in Fluidigm by 171.1% during the fourth quarter. Millennium Management LLC now owns 932,996 shares of the medical research company’s stock worth $8,042,000 after buying an additional 588,862 shares during the last quarter. RTW Investments LP bought a new stake in shares of Fluidigm during the fourth quarter valued at approximately $7,622,000. Finally, Acadian Asset Management LLC grew its stake in shares of Fluidigm by 57.0% during the first quarter. Acadian Asset Management LLC now owns 845,762 shares of the medical research company’s stock valued at $11,238,000 after purchasing an additional 307,013 shares during the last quarter. Institutional investors and hedge funds own 92.64% of the company’s stock.
Several analysts have recently commented on FLDM shares. Zacks Investment Research raised shares of HB Fuller from a “sell” rating to a “hold” rating in a research note on Wednesday, July 3rd. BidaskClub cut shares of Vertex Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Tuesday, July 9th. Piper Jaffray Companies increased their target price on shares of Marvell Technology Group from $22.00 to $30.00 and gave the stock an “overweight” rating in a report on Friday, May 3rd. Finally, ValuEngine lowered shares of Welbilt from a “hold” rating to a “sell” rating in a report on Wednesday, June 12th. One investment analyst has rated the stock with a sell rating, two have issued a hold rating and four have issued a buy rating to the company’s stock. The stock presently has a consensus rating of “Hold” and a consensus target price of $14.75.
Fluidigm (NASDAQ:FLDM) last announced its quarterly earnings data on Thursday, May 2nd. The medical research company reported ($0.44) EPS for the quarter, missing analysts’ consensus estimates of ($0.14) by ($0.30). Fluidigm had a negative net margin of 60.45% and a negative return on equity of 43.75%. The firm had revenue of $30.10 million during the quarter, compared to the consensus estimate of $29.18 million. Fluidigm’s revenue was up 19.4% on a year-over-year basis. As a group, analysts predict that Fluidigm Co. will post -0.5 earnings per share for the current fiscal year.
In other Fluidigm news, insider Levin Easterly Partners Llc sold 217,148 shares of Fluidigm stock in a transaction dated Tuesday, June 25th. The shares were sold at an average price of $12.28, for a total value of $2,666,577.44. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Nicolas Barthelemy sold 5,100 shares of Fluidigm stock in a transaction dated Monday, June 17th. The stock was sold at an average price of $12.43, for a total transaction of $63,393.00. The disclosure for this sale can be found here. Insiders have sold a total of 566,356 shares of company stock valued at $6,964,366 in the last ninety days. 2.20% of the stock is currently owned by insiders.
Fluidigm Company Profile
Fluidigm Corporation creates, manufactures, and markets technologies and tools for life sciences research in the United States and Europe. It offers analytical systems comprising Helios, a CyTOF system, Hyperion imaging system, and Hyperion tissue imager; and assays and reagents, including Maxpar reagents and Maxpar human immune monitoring panel kit and workflow.
Featured Article: Asset Allocation and Your Retirement
Receive News & Ratings for Fluidigm Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fluidigm and related companies with MarketBeat.com's FREE daily email newsletter.